Showing posts with label Growth Opportunities. Show all posts
Showing posts with label Growth Opportunities. Show all posts
Asthma Market to Witness the Highest Growth Globally in Coming Years
Asthma is a respiratory condition, where the airways become
inflamed and narrow, which can cause a serious and incurable condition if left
untreated. Breathlessness, wheezing and coughing are some of the symptoms of
asthma and it can be controlled by avoiding triggers and with the help of drug
therapy. Environmental triggers may vary from consumer to consumer but it can include
exercise, smoke, cold air and other allergens such as pollen, dust mites, and
infections. The wheezing in asthma begins when the chemicals present in the
lungs overreact to the dust mites, cold air and exercise.
According to Centers for Disease Control and Prevention
(CDC), asthma is an ordinary chronic airway disorder which is characterized by
swelling of air passages that convey air from mouth and nose to lungs. Asthma
is caused generally due to allergies leading to inflammation of lungs.
GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are
developing once-a-day combination products that are longer acting than
currently available drugs and more suitable for patients due to its advantage
of being taken only once a day.
Request to Get the Sample Pages at: 
Based on drug class, the global asthma market can be
categorized bronchodilators, combination therapies, mast cell stabilizers,
leukotriene antagonists and immunosuppressants. On the basis of route of
administration, the global market is segmented into oral, inhaled and other
route of administrations.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=asthma-market
Daily exposure to hazardous working environment, influx
of pollutants in the air, increase in population susceptible to indoor air
pollutants, increase in disposable income, increasing population of smokers,
improved healthcare facility, and growing aging population are some of other
the major factors that are driving the growth of asthma market. Factors that
are restraining the growth of asthma market are high cost of asthma treatment,
patent expiry of many best-seller brands and long treatment continuation.
Additionally, lack of diagnostic tools for reliable asthma diagnosis in young
children is also limiting the growth of global asthma market.
Some of the major competitors of global asthma market
are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical
Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion
Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke
Philips N.V., and F. Hoffmann La-Roche Ltd.
About P&S
Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider
of market research and consulting services catering to the market information
needs of burgeoning industries across the world. Providing the plinth of market
intelligence, P&S as an enterprising research and consulting company,
believes in providing thorough landscape analyses on the ever-changing market
scenario, to empower companies to make informed decisions and base their
business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Anti-Obesity Drugs Market Analysis by Top Companies, New Technology, Demand and Opportunity
The
global anti-obesity
drugs market is growing significantly, due to high
prevalence of obesity and rich pipeline for anti-obesity drugs. The presence of
large patient pool and massive unexplored market in the emerging economies,
such as India and China, are creating ample opportunities for the growth of the
global anti-obesity drugs market. The advanced research and development
facilities, and new drug developments by the key players are propelling the
demand for improved and cost-effective anti-obesity drugs, thus driving the
growth of the global anti-obesity drugs market.
Obesity
can be defined as a medical condition, in which excessive or abnormal
accumulation of fat occurs in a patient. A person with body mass index (BMI) of
30 or above is considered obese. There are several factors causing obesity,
such as eating habits, physical inactivity, and genetic makeup. Obesity has
serious negative impact on an individual’s health. An obese individual is at a
higher risk of developing chronic diseases, such as breast cancer, endometrial
cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and
musculoskeletal disorders. According to the WHO, in 2014, there were 600
million obese people aged 18 years or above, which accounted for 13% of the
total adult population in the world. The prevalence of obesity is the highest
in the U.S. According to the Center for Disease Control and Prevention (CDC),
in the U.S., 35.1% of the adult population aged 20 years or above were obese
during 2011 - 2012.
Request to
Get the Sample Pages at:
Geographically,
North America leads the global anti-obesity drugs market, due to high
incidences of obesity, high healthcare expenditure, and increased awareness
about obesity and obesity related risks among patients. In addition, the
increasing involvement of government and non-government organizations to
educate and aware people about the ill effects of obesity, and extensive
research and development activities for the development of anti-obesity drugs
are fueling the growth of the anti-obesity drugs market in North America.
Asia-Pacific is the fastest growing region in the global anti-obesity drugs
market. The fastest growth of the region is attributed to improving healthcare
infrastructure, growing healthcare expenditure and increasing geriatric
population. Moreover, the anti-obesity drugs market is growing due to increasing
research and development facilities, growing disposable income, and presence of
large patient pool in the emerging countries, such as India and China.
Some of the major
players operating in the global anti-obesity drugs market are F. Hoffmann-La
Roche AG, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc.,
GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co.
Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S,
Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, and Norgine B.V.
